|Articles|June 1, 2007

CYPHER Stent Continues to Prove Its Worth

Author(s)Susan Farley

A clinical trial comparing stents found that the CYPHER Sirolimus-eluting Coronary Stent had a clinical benefit similar to that of a bare metal stent (BMS), with no differences in incidence of heart attack, death, or blood clots. Data from this new trial support data from a previous trial touting CYPHER?s benefits. In fact, this trial showed that patients in the CYPHER group had significantly lower rates of target vessel failure at the 5-year follow-up than patients in the BMS group (22.5% vs 34.7%). At the long-term follow-up, the CYPHER stent also resulted in lower rates of re-treatment, myocardial infarction, and death, when compared with BMS (9.4% vs 24.2%).

Ms. Farley is a freelance medical writer based in Wakefield, RI.

Articles in this issue

over 18 years ago

Article

otc Product News

over 18 years ago

Article

case STUDIES

over 18 years ago

Article

can you READ these Rxs?

over 18 years ago

Article

compounding HOTLINE

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME